Login
DBV Technologies S.A. logo

DBV Technologies S.A.

dbv-technologies.com

What Do They Do?

Develops skin patches that deliver allergy treatments for children with food allergies, including peanut and milk allergies.

How Do They Make Money?

FY2025 revenue

Who Are Their Customers?

The company is developing treatments for children with food allergies and plans, if approved, to promote the peanut patch through allergists and pediatricians, with payer teams working on coverage.

Do Revenues Turn Into Profits?

No. It lost $146.9M in FY2025.

Operating income, FY2025
−2609% of revenue
▼ −26% (Loss) vs FY2024 (−$116.6M, −2809%)
Net income, FY2025
−2607% of revenue
▼ −29% (Loss) vs FY2024 (−$113.9M, −2744%)
Free cash flow, FY2025
−2160% of revenue
▼ −14% (Loss) vs FY2024 (−$106.8M, −2573%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −43%
vs $2.8M in Q3 FY2025
Net income
▼ −94% (Loss)
vs −$33.2M in Q3 FY2025
  • Jun 29, 2026 Delayed the planned peanut-patch application to the third quarter of 2026 After discussions with the FDA, the company said it needed more time to incorporate feedback on how existing data are organized and formatted; the agency did not request additional data.

Flat. Revenue was $5.6M in FY2025, about the same as the $5.7M of FY2021.

Who Do They Compete With?

Competes with Aimmune Therapeutics, Stallergenes Greer, and GSK

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support